{
    "nct_id": "NCT05555550",
    "official_title": "Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)",
    "inclusion_criteria": "* LGG including the brainstem and supratentorial only , (WHO grade I-II), confirmed by biopsy unless in Neurofibromatosis type 1 (NF1) participants with classic appearance\n* Participants must have evaluable disease (1x1 cm tumor on MRI; enhancing + non-enhancing tumor)\n* Scheduled to receive systemic therapy\n* Performance Score: Karnofsky ≥ 50 for participants &gt; 16 years of age and Lansky ≥ 50 for participants ≤ 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n* Age between ≥ 1 years but ≤21 years at time of study registration\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 21 Years",
    "exclusion_criteria": "1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n2. Pregnant participants\n3. Patient who would require sedation or anesthesia for imaging beyond SOC.\n4. Participants who weigh less than 8 kg.\n5. Participants who cannot avoid contact with a pregnant woman or infant for at least 12 hours following injection.\n6. Participants with a history of abnormal kidney function or creatinine &gt;= CTCAE v5.0 grade 2 at time of study registration.\n7. Participants with primary tumors of the spinal cord.",
    "miscellaneous_criteria": ""
}